BioWa Inc., (Princeton, NJ) has entered  into a second agreement with MedImmune to provide additional access to BioWa’s  patented Potelligent technology platform for the development of antibody-dependent  cellular cytotoxicity (ADCC) enhanced antibodies. 

The agreement grants to MedImmune  nonexclusive license rights to develop, manufacture, and market antibodies  based on Potelligent technology for an undisclosed number of targets. In  return, BioWa will receive certain fees and milestone payments from MedImmune  during product development and royalties on marketed products using ADCC  enhanced antibodies. 

Potelligent technology is designed to  improve the potency and efficacy of antibody therapeutics by enhancing  antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of  antibody therapeutics. Potelligent technology involves the reduction of  the amount of fucose in the carbohydrate structure of an antibody using a  proprietary fucosyltransferase-knockout CHO cell line as a production cell.  Research shows that Potelligent technology  significantly enhances ADCC activity of an antibody 

, thereby increasing the potential for improved activity 

News

BioWa Inc., (Princeton, NJ) has entered into a second agreement with MedImmune to provide additional access to BioWa’s patented Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.